Jacobs Levy Equity Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Sell	60,986 -151,218	-71%	-$45.6M	0.07%	235
2026 Q1	$70.2M	Sell	212,204 -189,167	-47%	-$64.4M	0.3%	88
2025 Q4	$160M	Sell	401,371 -8,971	-2%	-$3.97M	0.62%	36
2025 Q3	$187M	Buy	410,342 +392,668	+2,222%	+$160M	0.74%	24
2025 Q2	$5.76M	Sell	17,674 -135,296	-88%	-$37.4M	0.02%	401
2025 Q1	$41.3M	Buy	+152,970	New	+$39.3M	0.16%	137
2024 Q3	–	Sell	-13,283	Closed	-$3.23M	–	946
2024 Q2	$3.23M	Sell	13,283 -113,084	-89%	-$17.9M	0.01%	513
2024 Q1	$18.9M	Buy	+126,367	New	+$21.1M	0.08%	214
2022 Q3	–	Sell	-8,604	Closed	-$1.25M	–	983
2022 Q2	$1.25M	Sell	8,604 -22,670	-72%	-$3.22M	0.01%	698
2022 Q1	$5.11M	Sell	31,274 -36,472	-54%	-$5.56M	0.03%	414
2021 Q4	$11.5M	Buy	+67,746	New	+$12.6M	0.08%	274
2021 Q3	–	Sell	-1,525	Closed	-$259K	–	1031
2021 Q2	$259K	Sell	1,525 -6,777	-82%	-$993K	﹤0.01%	948
2021 Q1	$1.17M	Sell	8,302 -710	-8%	-$107K	0.01%	706
2020 Q4	$1.17M	Buy	9,012 +2,259	+33%	+$302K	0.01%	682
2020 Q3	$983K	Buy	+6,753	New	+$960K	0.01%	669
2019 Q4	–	Sell	-102,590	Closed	-$8.25M	–	990
2019 Q3	$8.25M	Buy	+102,590	New	+$8.12M	0.1%	246
2017 Q1	–	Sell	-12,100	Closed	-$453K	–	912
2016 Q4	$453K	Buy	+12,100	New	+$507K	0.01%	694
2016 Q3	–	Sell	-25,061	Closed	-$1.39M	–	1009
2016 Q2	$1.39M	Sell	25,061 -138,530	-85%	-$8.73M	0.03%	499
2016 Q1	$10.3M	Buy	+163,591	New	+$10.9M	0.22%	137
2015 Q3	–	Sell	-3,940	Closed	-$472K	–	800
2015 Q2	$472K	Sell	3,940 -3,500	-47%	-$418K	0.01%	578
2015 Q1	$777K	Buy	+7,440	New	+$754K	0.01%	529

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's ALNY Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 71% in Q2 2026, selling an estimated $45.6M and leaving 60,986 shares worth $18.4M. The position accounts for 0.07% of the portfolio, ranked #235.

Jacobs Levy Equity Management first reported a position in ALNY in Q1 2015 and has held it in 21 quarters since. The position peaked at $187M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Jacobs Levy Equity Management held 60,986 shares of Alnylam Pharmaceuticals worth $18.4M as of Q2 2026.
Jacobs Levy Equity Management sold 151,218 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $45.6M.
Alnylam Pharmaceuticals made up 0.07% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #235 holding.
Jacobs Levy Equity Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 21 quarters since.
Jacobs Levy Equity Management's Alnylam Pharmaceuticals position peaked at $187M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.